BioSpace News Archive

TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its second quarter 2022 financial results on Monday, August 15, 2022, at 8:30 a.m. ET prior the opening of the U.S. financial markets.

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for 124 I-AT-01 (iodine (I-124) evuzamitide) as a diagnostic for the management of transthyretin amyloidosis (ATTR).

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the second quarter of 2022 and highlighted recent progress across its business.

Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today reported financial results for the second quarter ended June 30, 2022.

PDS Biotechnology Corporation will discuss its financial results for the quarter ended June 30, 2022 and provide a business update on its conference call today.

Compugen Ltd. announced today that the European Patent Office has granted Compugen a new patent covering anti-PVRIG antibodies for use in cancer treatment.

TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial.

Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, reported financial results for the second quarter of 2022 and provided business updates.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the second quarter ended June 30, 2022 and provided a business update.

Todos Medical, Ltd. today announced that its CLIA/CAP-certified laboratory Provista Diagnostics has entered into two contracts to provide PCR-based MonkeyPox testing services.